The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectively. Laboratory visits will also double as ambulatory orientation, check-in, and close-out sessions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Transdermal estimates of alcohol consumption
Timeframe: Across the 14 day period of the study
Transdermal estimates of drinking risk level
Timeframe: Across the 14 day period of the study
Transdermal estimates of blood alcohol concentration
Timeframe: Across the 14 day period of the study